Search the full Beauty Signal index.
- Signals
PDRN Is the Dominant Ingredient Narrative in 2025–2026 K-Beauty — But the Credibility Question Is Unresolved
Mariko Lin · Ingredient IntelligenceFive of the twelve products on our K-beauty watch list lead with PDRN as a primary active. Its migration from clinical post-procedure repair to $25–$42 mass-market serums — without concentration disclosures — is the formulation-credibility gap the category hasn't yet answered.
pdrnk-beautyingredientscosrxanuaOpen → - Signals
COSRX Holds #1 Sunscreen on Amazon UK and Germany. This Is a Distribution Story, Not a Viral One.
Iris Halberg · Retail SignalsAn Amorepacific-backed K-beauty SPF is using Amazon as its European retail infrastructure — outflanking Douglas, Credo, and Space NK on speed and cost basis. This is what disruption from the East looks like in practice.
COSRXAmorepacificK-beautyAmazonSPFOpen → - Founders
Jun Sang Hun
COSRX · Seoul, South KoreaThe fewer ingredients in a formula, the more accurately you can identify what skin responds to.
COSRXCOSRX Inc., independent until November 2023; Amorepacific is now the largest shareholder.Open → - Products
The Blue Peptide Bakuchiol Plump Glow Serum
COSRX · Clean SkincareCOSRX's first major post-Amorepacific-acquisition launch pairing blue copper peptides with bakuchiol — the retinol-alternative active that's anchoring most of 2026's anti-aging launches. Priced at $27 and positioned as a daily 'plump and bounce' serum, this is COSRX moving up the formulation complexity curve while keeping the accessible price ladder that defined its US Amazon dominance.
COSRXMidOpen → - Products
5 PDRN Collagen Intense Vitalizing Serum
COSRX · Clean SkincareCOSRX's most formulation-complex PDRN play to date — five distinct PDRN sources in a single serum, launched on Amazon at $35–$45 for 100mL. The five-source claim is itself a competitive signal: most K-beauty PDRN launches lead with one salmon-derived source, and brands are increasingly using source-count as the differentiation axis. Credibility watch: no clinical-grade concentration disclosure.
COSRXMidOpen →